Tumor-Targeted Retrovector for Chemotherapy-Resistant Malignancies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly chemotherapy, often result in systemic and organ toxicity due to non-specific drug distribution, leading to resistance in cancer cells and the occurrence of secondary malignancies with low survival rates, as well as immune system suppression.
Innovation Solution
Administration of a tumor-targeted retrovector encoding a cytocidal dominant-negative cyclin G1 construct, such as DeltaRex-G, which selectively targets cancer cells, inhibiting the CCNG1 gene pathway to induce apoptosis and restore immune surveillance without systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy agents are administered to kill cancer cells, then cancer cell destruction is improved, but systemic and organ toxicity increases
Solution Approach 1:
The patent applies local quality by engineering retrovectors with tumor-specific targeting ligands (such as RGD peptides for integrin targeting) that enable selective accumulation of the therapeutic agent at the tumor site. This localized delivery ensures high concentrations of the cytocidal cyclin G1 construct are delivered to cancer cells while minimizing exposure to healthy tissues, thereby resolving the contradiction between effective cancer cell destruction and reduction of systemic toxicity
Solution Approach 2:
The patent uses retrovectors as intermediary carriers that mediate the delivery of the cytocidal cyclin G1 construct to tumor cells. These retrovectors serve as a bridge between the therapeutic gene and the target cells, enabling controlled transduction and expression of the anti-cancer protein specifically in tumor tissue through mechanisms such as receptor-mediated endocytosis, thus achieving cancer cell destruction without the broad systemic toxicity of conventional chemotherapy
2Reliability
If high plasma levels of chemotherapeutic agents are used to kill cancer cells, then cancer cell destruction is improved, but damage to healthy cells increases
Solution Approach 1:
The retroviral vector system enables local quality by concentrating the therapeutic effect at the tumor site through active targeting mechanisms. The vectors accumulate preferentially in tumor tissue via enhanced permeability and retention (EPR) effect and specific receptor binding, creating a localized high-concentration environment that destroys cancer cells while maintaining low systemic concentrations that spare healthy cells from damage
Solution Approach 2:
The patent employs self-service principles by designing retrovectors that autonomously navigate to and enter tumor cells through their inherent targeting capabilities and cell entry mechanisms. The vectors self-assemble, self-target, and self-deliver the cyclin G1 construct without requiring external assistance or high systemic drug levels, thereby achieving cancer cell destruction with minimal off-target effects on healthy cells
3Reliability
If chemotherapy is administered repeatedly to treat resistant cancer, then cancer cell control is improved, but occurrence of secondary malignancies increases
Solution Approach 1:
The patent extracts and eliminates cancer stem cells—the root cause of tumor recurrence and resistance—by delivering the cytocidal cyclin G1 construct specifically to these cells via retroviral transduction. By targeting and destroying the stem cell population that drives tumor regeneration and resistance development, the treatment achieves durable cancer cell control without the cumulative genotoxic damage that leads to secondary malignancies associated with repeated conventional chemotherapy
Solution Approach 2:
The patent converts the previously harmful effect of cyclin G1 (which can be toxic when overexpressed) into a beneficial therapeutic mechanism by using retrovectors to deliver controlled expression of the gene specifically in tumor cells. The cyclin G1 construct, when expressed at appropriate levels in cancer cells, induces apoptosis and eliminates resistant tumor populations, transforming a potentially harmful agent into a precise anti-cancer weapon that does not cause secondary malignancies
4Productivity
If conventional chemotherapy is used to treat advanced cancer, then initial tumor response is improved, but long-term survival is reduced due to resistance
Solution Approach 1:
The patent applies preliminary action by using retrovectors to pre-deliver and establish sustained expression of the cytocidal cyclin G1 construct within tumor cells before resistance can develop. The retroviral integration into the genome ensures long-term, continuous production of the anti-cancer protein at the tumor site, providing prolonged therapeutic pressure that prevents resistance emergence and maintains tumor control over extended periods, thereby improving long-term survival
Solution Approach 2:
The patent achieves continuity of useful action through the persistent expression of cyclin G1 from the integrated retroviral construct in tumor cells. This continuous local production of the therapeutic protein maintains constant anti-cancer activity at the tumor site without the interruptions and resistance development associated with periodic systemic chemotherapy, ensuring sustained tumor cell destruction and improved long-term outcomes
Data Source
AI summary
Disclosed are methods for treating an individual with a chemotherapy-resistant primary and/or secondary malignancy that comprise administering a therapeutically effective amount of a tumor-targeted retrovector encoding a cytocidal dominant-negative Cyclin G1 construct, such as DeltaRex-G, to the individual. Also disclosed are methods in which DeltaRex-G, either alone or in conjunction with other cancer therapies and/or treatments, may be administered to ameliorate or eliminate the life-threatening effects of metastatic cancer.